Glenmark Pharma bags USFDA nod for generic version of Enstilar Foam
Mumbai: Drugmaker, Glenmark Pharmaceuticals Inc., USA, today announced that it has received tentative approval from the United States Food & Drug Administration (USFDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%, the generic version of Enstilar Foam, 0.005%|0.064%, of Leo Pharma AS.Betamethasone dipropionate is used to treat inflammation of the...
Mumbai: Drugmaker, Glenmark Pharmaceuticals Inc., USA, today announced that it has received tentative approval from the United States Food & Drug Administration (USFDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%, the generic version of Enstilar Foam, 0.005%|0.064%, of Leo Pharma AS.
Betamethasone dipropionate is used to treat inflammation of the skin and dermatitis while calcipotriene is used to treat plaque psoriasis of the skin and scalp.
According to IQVIA sales data for the 12 month period ending March 2022, the Enstilar Foam, 0.005%|0.064% market achieved annual sales of approximately $115.2 million*.
Read also: Glenmark Pharma reports revenue growth of 13.9 percent in Q3
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the U.S. FDA.
In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Read also: Glenmark gets CDSCO panel nod for Phase 4 study of anti-diabetic FDC drug
